Home › Funds › JOHNSON INVESTMENT COUNSEL INC › ABT
JOHNSON INVESTMENT COUNSEL INC position in ABT
ABBOTT LABORATORIES · Health Care
JOHNSON INVESTMENT COUNSEL INC reported holding 986,617 shares of ABT (ABBOTT LABORATORIES) in its Q2 2026 13F filing — a position valued at US$89.5M, representing 0.65% of its reported portfolio and ranking #42 among its reported holdings. JOHNSON INVESTMENT COUNSEL INC has disclosed ABT holdings in 11 of the last 12 reported quarters, going back to Q3 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How JOHNSON INVESTMENT COUNSEL INC's ABT position evolved
JOHNSON INVESTMENT COUNSEL INC first disclosed a stake in ABT in Q3 2023 at 972,417 shares (US$94.2M). The position peaked in Q2 2025 at 988,641 shares, worth US$134.5M. Across 11 filings, JOHNSON INVESTMENT COUNSEL INC increased the stake 3 time(s), trimmed it 4 time(s) and left it unchanged 2 time(s). The most recent filing (Q2 2026) shows 986,617 shares valued at US$89.5M — a reduction of -36,126 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 972.42K | $94.18M | New |
| Q4 2023 | 976.72K | $107.51M | Hold |
| Q2 2024 | 998.95K | $103.80M | New |
| Q3 2024 | 997.21K | $113.69M | Hold |
| Q4 2024 | 1.01M | $114.19M | Add |
| Q1 2025 | 999.89K | $132.63M | Reduce |
| Q2 2025 | 988.64K | $134.47M | Reduce |
| Q3 2025 | 975.88K | $130.71M | Reduce |
| Q4 2025 | 985.96K | $123.53M | Add |
| Q1 2026 | 1.02M | $105.01M | Add |
| Q2 2026 | 986.62K | $89.53M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ABT and 13F data
ABT (ABBOTT LABORATORIES) is a Health Care company. 20 other funds we track also report a position in ABT — the largest reported positions include Vanguard Group (US$22.00B), Charles Schwab Investment Management (US$5.41B), CHARLES SCHWAB INVESTMENT MANAGEMENT INC (US$5.41B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ABT
- Vanguard Group 175.56M sh · $22.00B · Q4 2025
- Charles Schwab Investment Management 59.67M sh · $5.41B · Q2 2026
- CHARLES SCHWAB INVESTMENT MANAGEMENT INC 59.67M sh · $5.41B · Q2 2026
- Sixth Street Partners Management Company, L.P. 59.67M sh · $5.41B · Q2 2026
- Capital Research Global Investors 36.91M sh · $3.35B · Q2 2026
- Capital Research Global Investors 36.91M sh · $3.35B · Q2 2026
- Capital International Investors 34.65M sh · $3.15B · Q2 2026
- Deutsche Bank AG 16.71M sh · $1.52B · Q2 2026
More on JOHNSON INVESTMENT COUNSEL INC
FAQ
How long has JOHNSON INVESTMENT COUNSEL INC held ABT?
JOHNSON INVESTMENT COUNSEL INC has disclosed ABT holdings in 11 of the last 12 reported quarters, going back to Q3 2023.
What is JOHNSON INVESTMENT COUNSEL INC's current position in ABT?
As of Q2 2026, JOHNSON INVESTMENT COUNSEL INC holds 986.62K shares of ABT (ABBOTT LABORATORIES), valued at $89.53M, representing 0.65% of its reported portfolio and ranking #42.
Has JOHNSON INVESTMENT COUNSEL INC been buying or selling ABT?
In the latest 13F filing (Q2 2026), JOHNSON INVESTMENT COUNSEL INC reduced its position in ABT. The position peaked in Q2 2025 at 988.64K shares.
Which other funds hold ABT?
Other major institutional holders of ABT include Vanguard Group, Charles Schwab Investment Management, CHARLES SCHWAB INVESTMENT MANAGEMENT INC, among 20 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.